URGN
Company Description
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102, which is in Phase III clinical trials for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial carcinoma and low-grade non-muscle invasive bladder cancer. It is also developing UGN-301 for the treatment of high-grade non-muscle invasive bladder cancer. The company has a license agreement with Allergan Pharmaceuticals International Limited for developing and commercializing pharmaceutical products that contain RTGel and clostridial toxins; Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and strategic research collaboration with MD Anderson to advance investigational treatment for high-grade bladder cancer. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.
Track Record
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 109.79M | 90.40M | 82.71M | 64.36M | 48.04M | 11.80M | 18,000 | 1.13M | 8.16M | 17.53M | 0 | 0 |
| Net Income | (153.49M) | (126.87M) | (102.24M) | (109.78M) | (110.82M) | (128.48M) | (105.15M) | (75.66M) | (20.00M) | (1.94M) | (12.69M) | (4.56M) |
| EPS | -3.19 | -2.96 | -3.55 | -4.79 | -4.96 | -5.90 | -4.90 | -4.80 | -2.06 | -0.16 | -5.51 | -1.98 |
| Free Cash Flow | (162.73M) | (97.06M) | (76.57M) | (87.81M) | (85.64M) | (107.10M) | (71.34M) | (37.89M) | (9.84M) | 3.49M | N/A | N/A |
| FCF / Share | -3.38 | -2.26 | -2.66 | -3.85 | -3.83 | -4.92 | -3.48 | -2.41 | -1.01 | 0.29 | N/A | N/A |
| Operating CF | (162.44M) | (96.77M) | (76.38M) | (87.56M) | (84.89M) | (105.89M) | (71.02M) | (37.33M) | (9.57M) | 4.19M | N/A | N/A |
| Total Assets | 200.46M | 285.71M | 178.31M | 135.62M | 119.75M | 122.00M | 202.39M | 103.56M | 75.55M | 23.06M | N/A | N/A |
| Total Debt | 128.33M | 123.39M | 99.39M | 99.12M | 398,000 | 1.50M | 2.60M | 0 | 0 | 0 | N/A | N/A |
| Cash & Equiv | 110.75M | 171.99M | 95.00M | 55.41M | 44.36M | 52.86M | 49.69M | 101.32M | 37.00M | 21.36M | N/A | N/A |
| Book Value | (105.47M) | (8.80M) | (65.21M) | (89.36M) | 8.41M | 96.36M | 180.30M | 90.09M | 68.52M | 16.31M | N/A | N/A |
| Return on Equity | N/A | N/A | N/A | N/A | -13.17 | -1.33 | -0.58 | -0.84 | -0.29 | -0.12 | N/A | N/A |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 50.96M | 37.84M | 27.48M | 24.21M | 20.25M | 24.57M | 25.20M | 21.85M | 18.78M | 23.53M | 20.85M | 21.14M |
| Net Income | (23.57M) | (26.36M) | (33.35M) | (49.94M) | (43.84M) | (37.51M) | (23.67M) | (33.40M) | (32.29M) | (26.02M) | (21.88M) | (24.14M) |
| EPS | -0.47 | -0.54 | -0.69 | -1.05 | -0.92 | -0.80 | -0.55 | -0.91 | -0.97 | -0.72 | -0.68 | -1.03 |
| Free Cash Flow | (45.37M) | (38.34M) | (42.36M) | (39.97M) | (42.07M) | (13.73M) | (27.76M) | (23.83M) | (31.73M) | (13.11M) | (17.40M) | (20.29M) |
| FCF / Share | -0.90 | -0.78 | -0.88 | -0.84 | -0.89 | -0.29 | -0.64 | -0.65 | -0.95 | -0.36 | -0.54 | -0.86 |
| Operating CF | (45.32M) | (38.33M) | (42.27M) | (39.83M) | (42.02M) | (13.62M) | (27.66M) | (23.75M) | (31.73M) | (13.06M) | (17.30M) | (20.27M) |
| Total Assets | 253.69M | 200.46M | 185.05M | 208.72M | 247.62M | 285.71M | 301.94M | 281.85M | 200.57M | 178.31M | 193.63M | 95.36M |
| Total Debt | 197.09M | 128.33M | 129.94M | 127.47M | 124.95M | 123.39M | 121.92M | 98.24M | 99.01M | 100.21M | 99.54M | 99.50M |
| Cash & Equiv | 111.30M | 110.75M | 90.04M | 92.90M | 104.03M | 171.99M | 124.92M | 219.97M | 132.26M | 95.82M | 119.31M | 20.13M |
| Book Value | (124.25M) | (105.47M) | (115.41M) | (93.38M) | (46.46M) | (8.80M) | 25.52M | 30.31M | (40.13M) | (65.21M) | (41.99M) | (138.43M) |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | -0.93 | -1.10 | N/A | N/A | N/A | N/A |
